BofA/Merrill Lynch analyst Kevin Fischbeck upgraded Mednax (NYSE: MD) from Underperform to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE